MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. HUM
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Humana (HUM) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Humana
NYSE•Healthcare•Healthcare Plans
$384.52-0.20(<0.01%)After hours
Market Cap
$46.02B
P/E
36.0x
P/S
0.3x
P/B
2.4x

Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit managers. Its CenterWell segment operates full-service, value-based senior focused primary care centers under the Conviva Senior Primary Care and CenterWell Senior Primary Care brands; a management services organization; CenterWell Home Health, a home health provider; and OneHome, which manages post-acute patient needs, as well as provides pharmacy and hospice solutions. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

C

How this company scores

AverageMetricSide Score: 52/100

Strongest: Growth (17/25); weakest: Profitability (6/25).

Profitability6/25
Growth17/25
Balance Sheet & Red Flags15/25
Cash & Earnings Quality14/25
Strengths
Growing revenueCash-backed earningsConsistent growthNo share dilution

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 36.0x5y range 16.4x – 36.0x
P/E 36.0x · above its 20-quarter median

Currently above its 20-quarter median.

P/S · 0.3x5y range 0.1x – 0.7x
P/S 0.3x · below its 20-quarter median

Currently below its 20-quarter median.

P/B · 2.4x5y range 1.1x – 4.2x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 36.8% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Cash Burn

Watch

FCF turned negative in 2 of the last 8 quarters — occasional cash consumption.

Price & Volume
Market Cap $46.02B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$145.68B
7Q
Q. Revenue
$40.87B
2Q
TTM EBITDA
$3.37B
17%
TTM Op. Income
$2.71B
18%
Q. Op. Income
$1.36B
24%
TTM Net Income
$1.28B
19%
Q. Net Income
$694.00M
27%
EPS
$5.78
28%
Shares Out.
$120.07M
2Q
$145.68B in TTM revenue grew 18.3% YoY, reaching $40.87B last quarter. TTM EBITDA of $3.37B and TTM operating income of $2.71B show growth is flowing through to the bottom line. TTM net income of $1.28B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin
3.7%
6%
Op. Margin
3.3%
2%
Net Margin
1.7%
1%
Op. margin of 3.3% is down 0.1% YoY — costs are rising relative to revenue. Net margin at 1.7% Over the past year, operating margin is down 2% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
36.0x
92%
P/S Ratio
0.3x
32%
P/B Ratio
2.4x
48%
At 36.0x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 0.3x and P/B of 2.4x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 92% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$57.20B
2Q
Cash
$6.89B
2Q
Long-Term Debt
$11.98B
3Q
Book Value
$19.21B
2Q
D/E Ratio
0.6
2Q
Debt/EBITDA
7.9
36%
With $57.20B in assets and $11.98B in long-term debt, D/E is 0.6and book value is $19.21B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 2 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$1.97B
2Q
TTM Free Cash Flow
$1.95B
2Q
FCF Margin
1.3%
2Q
FCF / Net Income
1.5
2Q
TTM FCF of $1.95B on $1.97B in operating cash flow. The FCF / Net Income ratio of 1.5x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 2.4x
· near its 20-quarter median

Currently near its 20-quarter median.